Amantadine therapy in traumatic brain injury patients

Journal of Pharmacy Technology

Volumn 23, Issue 2, 2007, Pages 95-103

  Villareal, Carolyn L ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE;

BEHAVIOR DISORDER; BEHAVIOR THERAPY; BIOSIS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EDEMA; FOOT EDEMA; HUMAN; HYPERACTIVITY; HYPOMANIA; IRRITABILITY; LENGTH OF STAY; LEUKOPENIA; MEDLINE; MOTOR DYSFUNCTION; NAUSEA; NEUROPSYCHOLOGICAL TEST; OUTCOMES RESEARCH; RASH; RATING SCALE; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; TIC; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL HALLUCINATION; VOMITING;

EID: 34247193158     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250702300206     Document Type: Review

References (61)

1. Langlois JA, Rutland-Brown W, Thomas KE. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, 2006.
2. Thurman DJ, Alverson C, Dunn KA, Guerrero J, Sniezek JE. Traumatic brain injury in the United States: a public health perspective. J Head Trauma Rehabil 1999;14:602-15.
3. Jorge RE. Neuropsychiatric consequences of traumatic brain injury: a review of recent findings. Curr Opin Psychiatry 2005;18:289-99.
4. Rao V, Lyketsos CG. Psychiatric aspects of traumatic brain injury. Psychiatr Clin North Am 2002;25:43-69.
5. Shutter LA, Colohan ART. Posttraumatic agitation: psychopharmacology and early management. Neurologist 1999;5:258-70.
6. Sandel ME, Bell KR, Michaud LJ. Brain injury rehabilitation. 1. Traumatic brain injury: prevention, pathophysiology, and outcome prediction. Arch Phys Med Rehabil 1998;79(suppl 1):S3-S9.
7. Sandel ME, Mysiw WJ. The agitated brain injured patient. Part 1: definitions, differential diagnosis, and assessment. Arch Phys Med Rehabil 1996;77:617-23.
8. Mysiw WJ, Sandel ME. The agitated brain injured patient. Part 2: pathophysiology and treatment. Arch Phys Med Rehabil 1997;78:213-20.
9. Lombard LA, Zafonte RD. Agitation after traumatic brain injury: considerations and treatment options. Am J Phys Med Rehabil 2005;84:797-812.
10. McIntosh TK, Juhler M, Wieloch T. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: 1998. J Neurotrauma 1998;15:731-69.
11. Meythaler JM, Peduzzi JD, Eleftheriou E, Novack TA. Current concepts: diffuse axonal injury-associated traumatic brain injury. Arch Phys Med Rehabil 2001;82:1461-71.
12. Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006;6:53-60.
13. Bakay RA, Sweeney KM, Wood JH. Pathophysiology of cerebrospinal fluid in head injury: Part 1. Pathological changes in cerebrospinal fluid solute composition after traumatic injury. Neurosurgery 1986;18:234-43.
14. Gennarelli TA. The pathobiology of traumatic brain injury. Neuroscientist 1997;3:73-81.
15. Whiting MD, Hamm RJ. Treating chronic cognitive impairment after traumatic brain injury: a review of post-traumatic neurotransmitter-based interventions. Crit Rev Phys Rehabil Med 2004;16:273-90.
16. Salmond CH, Chatfield DA, Menon DK, Pickard JD, Sahakian BJ. Cognitive sequelae of head injury: involvement of basal forebrain and associated structures. Brain 2005;128(pt 1):189-200.
17. Yan HQ, Kline AE, Ma X, Li Y, Dixon CE. Traumatic brain injury reduces dopamine transporter protein expression in the rat frontal cortex. Neuroreport 2002;13:1899-901.
18. Levin H, Kraus MF. The frontal lobes and traumatic brain injury. J Neuropsychiatry Clin Neurosci 1994;6:443-54.
19. Fujinaka T, Kohmura E, Yuguchi T, Yoshimine T. The morphological and neurochemical effects of diffuse brain injury on rat central noradrenergic system. Neurol Res 2003;25:35-41.
20. Cardenas DD, McLean A. Psychopharmacologic management of traumatic brain injury. Phys Med Rehabil Clin North Am 1992;3:273-90.
21. Gianutsos G, Chute S, Dunn JP. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 1985;110:357-61.
22. DeMarchi R, Bansal V, Hung A, et al. Can J Neurol Sci 2005;32:4-17.
23. Leone H, Polsonetti BW. Amantadine for traumatic brain injury: does it improve cognition and reduce agitation? J Clin Pharm Ther 2005;30:101-4.
24. Cowell LC, Cohen RF. Amantadine: a potential adjuvant therapy following traumatic brain injury. J Head Trauma Rehabil 1995;10:91-4.
25. Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury: part 2. J Head Trauma Rehabil 2001;16:112-6.
26. Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994;43:91-104.
27. Zasler ND. Advances in neuropharmacological rehabilitation for brain dysfunction. Brain Inj 1992;6:1-14.
28. Andersson S, Berstad J, Finset A, Grimsmo J. Amantadine in cognitive failure in patients with traumatic head injuries. Tidsskr Nor Laegeforen 1992;112:2070-2.
29. Beers SR, Skold A, Dixon CE, Adelson PD. Neurobehavioral effects of amantadine after pediatric traumatic brain injury: a preliminary report. J Head Trauma Rehabil 2005;20:450-63.
30. Green LB, Hornyak JE, Hurvitz EA. Amantadine in pediatric patients with traumatic brain injury: a retrospective, case-controlled study. Am J Phys Med Rehabil 2004;83:893-7.
31. Patrick PD, Buck ML, Conaway MR, Blackman JA. The use of dopamine enhancing medications with children in low response states following brain injury. Brain Inj 2003;17:497-506.
32. Kraus MF, Maki P. The combined use of amantadine and 1-dopa/carbidopa in the treatment of chronic brain injury. Brain Inj 1997;11:455-60.
33. Rosati DL. Early polyneuropharmacologic intervention in brain injury agitation. Am J Phys Med Rehabil 2002;81:90-3.
34. Karli DC, Burke DT, Kim HJ, et al. Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation. Brain Inj 1999;13:63-8.
35. Sugden SG, Kile SJ, Farrimond DD, Hilty DM, Bourgeois JA. Pharmacological intervention for cognitive deficits and aggression in frontal lobe injury. NeuroRehabilitation 2006;21:3-7.
36. Gualtieri T, Chandler M, Coons TB, Brown LT. Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol 1989;12:258-70.
37. Greer N, Mosser G, Logan G, Halaas GW. A practical approach to evidence grading. Jt Comm J Qual Improv 2000;26:700-12.
38. Wu TS, Garmel GM. Improved neurological function after amantadine treatment in two patients with brain injury. J Emerg Med 2005;28:289-92.
39. Saniova B, Drobny M, Kneslova L, Minarik M. The outcome of patients with severe head injuries treated with amantadine sulphate. J Neural Transm 2004;111:511-4.
40. Hughes S, Colantonio A, Santaguida PL, Paton T. Amantadine to enhance readiness for rehabilitation following severe traumatic brain injury. Brain Inj 2005;19:1197-206.
41. Zafonte RD, Watanabe T, Mann NR. Amantadine: a potential treatment for the minimally conscious state. Brain Inj 1998;12:617-21.
42. Cheng SK, Man DW. Management of impaired self-awareness in persons with traumatic brain injury. Brain Inj 2006;20:621-8.
43. Shiller AD, Burke DT, Kim HJ, Calvanio R, Dechman KG, Santini C. Treatment with amantadine potentiated motor learning in a patient with traumatic brain injury of 15 years' duration. Brain Inj 1999;13:715-21.
44. Chandler MC, Barnhill JL, Gualteri CT. Amantadine for the agitated head-injury patient. Brain Inj 1988;2:309-11.
45. Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci 1997;9:222-30.
46. Van Reekum R, Bayley M, Garner S, et al. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995;9:49-53.
47. Nickels JL, Schneider WN, Dombovy ML, Wong TM. Clinical use of amantadine in brain injury rehabilitation. Brain Inj 1994;8:709-18.
48. Raffaele R, Nicoletti G, Vecchio I, et al. Use of amantadine in the treatment of the neurobehavioral sequelae after brain injury in elderly patients. Arch Gerontol Geriatr Suppl 2002;8:309-12.
49. Kraus MF, Smith GS, Butters M, et al. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Inj 2005;19:471-9.
50. Schneider WN, Drew-Cates J, Wong TM, Dombovy ML. Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study. Brain Inj 1999;13:863-72.
51. Larson EB, Ellsworth AJ, Oas J. Randomized clinical trials in single patients during a two-year period. JAMA 1993;270:2708-12.
52. Jull A, Bennett D. Do N-of-1 trials really tailor treatment? Lancet 2005;365:1992-4.
53. Larson EB. N-of-1 clinical trials - a technique for improving medical therapeutics. West J Med 1990;152:52-6.
54. Karnon J, Qizilbash N. Economic evaluation alongside N-of-1 trials: getting closer to the margin. Health Econ 2001;10:79-82.
55. Zucker DR, Schmid CH, Mcintosh MW, D'Agostino RB, Selker HP, Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual responses to treatment. J Clin Epidemiol 1997;50:401-10.
56. Vanier M, Mazaux JM, Lambert J, Dassa C, Levin HS. Assessment of neuropsychologic impairments after head injury: interrater reliability and factorial and criterion validity of the Neurobehavioral Rating Scale-Revised. Arch Phys Med Rehabil 2000;81:796-806.
57. Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil 2002;17:300-13.
58. Hannay HJ, Ezrachi O, Contant CF, Levin HS. Outcome measures for patients with head injuries: report of the Outcome Measures Subcommittee. J Head Trauma Rehabil 1996;11:41-50.
59. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269:2386-91.
60. Cowen TD, Meythaler JM, DeVivo MJ, Ivie CS, Lebow J, Novack TA. Influence of early variables in traumatic brain injury on functional independence measure scores and rehabilitation length of stay and charges. Arch Phys Med Rehabil 1995;76:797-803.
61. 2005 Drug topics redbook. Montvale, NJ: Medical Economics, 2005.